Zenas BioPharma, Inc. (ZBIO) Revenue History
Annual and quarterly revenue from 2022 to present
ZBIO Revenue Over Time (2022–2025)
ZBIO Revenue Growth History
1 of 2 years with positive growth- FY2022 revenue growth
- N/A
- FY2023 revenue growth
- N/A
- FY2024 revenue growth
- -90.0%
- FY2025 revenue growth
- +100.0%
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $0 | -100.0% |
| Q4 2025 | $0 | -100.0% |
| Q3 2025 | $0 | — |
| Q2 2025 | $0 | — |
| Q1 2025 | $10.0M | — |
| Q4 2024 | $5.0M | — |
| Q3 2024 | $0 | -100.0% |
| Q2 2024 | $0 | — |
Multi-year avg. share of annual revenue by fiscal quarter
ZBIO Revenue Analysis (2022–2025)
Current Revenue & Growth
As of June 12, 2026, Zenas BioPharma, Inc. (ZBIO) generated trailing twelve-month (TTM) revenue of $0, reflecting significant decline in growth of -100.0% year-over-year. The most recent quarter (Q1 2026) recorded $0 in revenue
Historical Growth Trajectory
ZBIO's historical revenue data shows various trends over time. Zenas BioPharma, Inc.'s highest annual revenue of $50.0 million was recorded in 2023.
Peer Comparison
Compared to Healthcare sector peers — including ARCT (-66.4% YoY), ARDX (+18.2% YoY), and KYMR (-12.6% YoY) — ZBIO has underperformed the peer group in revenue growth. Compare ZBIO vs ARCT →
ZBIO Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
 ZBIOCurrent | $0 | -100.0% | - | -2113.8% | |
 ARCT | $67M | -66.4% | +47.8% | -111.5% | |
 ARDX | $407M | +18.2% | +121.9% | -10.1% | |
 KYMR | $39M | -12.6% | +2.9% | -891.3% |
ZBIO Historical Revenue Data (2022–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $10.0M | +100.0% | $10.0M | 100.0% | $-211,385,000 | -2113.8% |
| 2024 | $5.0M | -90.0% | $-134,139,000 | -2682.8% | $-163,888,000 | -3277.8% |
| 2023 | $50.0M | - | $50.0M | 100.0% | $-37,147,000 | -74.3% |
| 2022 | $0 | - | $-61,689,000 | - | $-76,199,000 | - |
What if you invested $1,000 in ZBIO back in 2022?
Total return with dividends reinvested · 4+ years of data
Calculate ReturnsHow much would $100/month in ZBIO be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs ZBIO Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationZBIO vs LLY — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.
Compare NowZBIO — Frequently Asked Questions
Quick answers to the most common questions about buying ZBIO stock.
Is ZBIO's revenue growth accelerating or slowing?
ZBIO revenue is declining -100.0% year-over-year. TTM revenue fell to $0.00, contrasting with the 5-year CAGR of N/A. The reversal reflects either macro headwinds or company-specific challenges.
What is ZBIO's revenue history from 2022 to 2026?
Zenas BioPharma, Inc. (ZBIO) revenue history spans 2022 to 2026. TTM revenue as of 2026 is $0.00, growing at -100.0% YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is ZBIO's long-term revenue growth rate (CAGR)?
Zenas BioPharma, Inc.'s 5-year revenue CAGR of N/A reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of -100.0% is below this long-term average. CAGR is the most reliable measure of sustained revenue momentum for ZBIO.
Why does ZBIO's quarterly revenue fluctuate?
ZBIO quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Zenas BioPharma, Inc.'s revenue data from 2022 to 2026 shows full historical quarterly detail on this page.
How is ZBIO's revenue distributed by segment?
ZBIO reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does ZBIO's revenue compare to industry peers?
Zenas BioPharma, Inc. (ZBIO) with TTM revenue of $0.00 and -100.0% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.